Triple-negative breast cancer (TNBC), which accounts for approximately 15–20% of all breast cancer cases, is defined by the absence of estrogen receptor, progesterone receptor, and the lack of human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification [1]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.